Myoscint
Executive Summary
Injectable radiolabeled monoclonal antibody cancer imaging agent is Centocor's pending product, not Cytogen's ("The Pink Sheet" March 9, p. 19). Myoscint was recommended for approval by an FDA advisory committee for imaging dead cardiac tissue on Nov. 26. Cytogen's OncoScint was recommended for ovarian and colorectal cancer imaging on Jan. 16.